.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Cipla
US Department of Justice
Colorcon
Dow
Baxter
Citi
Julphar
Chinese Patent Office
Express Scripts

Generated: July 23, 2017

DrugPatentWatch Database Preview

EVISTA Drug Profile

« Back to Dashboard

Which patents cover Evista, and what generic Evista alternatives are available?

Evista is a drug marketed by Lilly and is included in one NDA. There are four patents protecting this drug.

This drug has forty-three patent family members in thirty-three countries.

The generic ingredient in EVISTA is raloxifene hydrochloride. There are fifteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the raloxifene hydrochloride profile page.

Summary for Tradename: EVISTA

Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list7
Bulk Api Vendors: see list68
Clinical Trials: see list17
Patent Applications: see list2,157
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:EVISTA at DailyMed

Pharmacology for Tradename: EVISTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly
EVISTA
raloxifene hydrochloride
TABLET;ORAL020815-001Dec 9, 1997ABRXYesYes8,030,330► SubscribeY ► Subscribe
Lilly
EVISTA
raloxifene hydrochloride
TABLET;ORAL020815-001Dec 9, 1997ABRXYesYes6,458,811► SubscribeYY ► Subscribe
Lilly
EVISTA
raloxifene hydrochloride
TABLET;ORAL020815-001Dec 9, 1997ABRXYesYes6,797,719► SubscribeY ► Subscribe
Lilly
EVISTA
raloxifene hydrochloride
TABLET;ORAL020815-001Dec 9, 1997ABRXYesYes6,894,064► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EVISTA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly
EVISTA
raloxifene hydrochloride
TABLET;ORAL020815-001Dec 9, 19975,731,327► Subscribe
Lilly
EVISTA
raloxifene hydrochloride
TABLET;ORAL020815-001Dec 9, 19976,797,719► Subscribe
Lilly
EVISTA
raloxifene hydrochloride
TABLET;ORAL020815-001Dec 9, 19975,478,847► Subscribe
Lilly
EVISTA
raloxifene hydrochloride
TABLET;ORAL020815-001Dec 9, 19978,030,330► Subscribe
Lilly
EVISTA
raloxifene hydrochloride
TABLET;ORAL020815-001Dec 9, 19975,514,826► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: EVISTA

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
► Subscribe
EVISTA
► Subscribe
► Subscribe
EVISTA
► Subscribe

International Patent Family for Tradename: EVISTA

Country Document Number Estimated Expiration
Malaysia115533► Subscribe
China1213967► Subscribe
United Kingdom9607110► Subscribe
Denmark0910369► Subscribe
Czech Republic300341► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: EVISTA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/048United Kingdom► SubscribePRODUCT NAME: RALOXIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/98/073/001 19980805; UK EU/1/98/073/002 19980805; UK EU/1/98/073/003 19980805; UK EU/1/98/073/004 19980805; UK EU/1/98/074/001 19980805; UK EU/1/98/074/002 19980805; UK EU/1/98/074/003 19980805; UK EU/1/98/074/004 19980805
0044Netherlands► SubscribePRODUCT NAME: RALOXIFENE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/98/073/001 - EU/1/98/073/004, EU/1/98/074/001 - EU/1/98/074/004 19980805 EU/1/98/073/001
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
McKinsey
Harvard Business School
Federal Trade Commission
Julphar
Deloitte
Covington
Novartis
Moodys
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot